212 related articles for article (PubMed ID: 32924017)
21. Recent advances on NOTCH signaling in T-ALL.
Tzoneva G; Ferrando AA
Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
[TBL] [Abstract][Full Text] [Related]
22. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
[TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
[TBL] [Abstract][Full Text] [Related]
24. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
25. Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress.
Melnick A; Liang S; Liu Y; Wang Q; Dean N; Choe E; Kunnath N; Bodanapu G; Mullin C; Akter F; Lin K; Magnuson B; Kumar S; Lombard DB; Muntean AG; Ljungman M; Sekiguchi J; Ryan RJH; Chiang MY
bioRxiv; 2023 Feb; ():. PubMed ID: 36711472
[TBL] [Abstract][Full Text] [Related]
26. Notch dimerization is required for leukemogenesis and T-cell development.
Liu H; Chi AW; Arnett KL; Chiang MY; Xu L; Shestova O; Wang H; Li YM; Bhandoola A; Aster JC; Blacklow SC; Pear WS
Genes Dev; 2010 Nov; 24(21):2395-407. PubMed ID: 20935071
[TBL] [Abstract][Full Text] [Related]
27. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells.
Wang H; Zou J; Zhao B; Johannsen E; Ashworth T; Wong H; Pear WS; Schug J; Blacklow SC; Arnett KL; Bernstein BE; Kieff E; Aster JC
Proc Natl Acad Sci U S A; 2011 Sep; 108(36):14908-13. PubMed ID: 21737748
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines.
Liu S; Breit S; Danckwardt S; Muckenthaler MU; Kulozik AE
Ann Hematol; 2009 Jul; 88(7):613-21. PubMed ID: 19057901
[TBL] [Abstract][Full Text] [Related]
30. The PIAS-like Coactivator Zmiz1 Is a Direct and Selective Cofactor of Notch1 in T Cell Development and Leukemia.
Pinnell N; Yan R; Cho HJ; Keeley T; Murai MJ; Liu Y; Alarcon AS; Qin J; Wang Q; Kuick R; Elenitoba-Johnson KS; Maillard I; Samuelson LC; Cierpicki T; Chiang MY
Immunity; 2015 Nov; 43(5):870-83. PubMed ID: 26522984
[TBL] [Abstract][Full Text] [Related]
31. Notch Partners in the Long Journey of T-ALL Pathogenesis.
Toribio ML; González-García S
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674902
[TBL] [Abstract][Full Text] [Related]
32. Stabilization of Notch1 by the Hsp90 Chaperone Is Crucial for T-Cell Leukemogenesis.
Wang Z; Hu Y; Xiao D; Wang J; Liu C; Xu Y; Shi X; Jiang P; Huang L; Li P; Liu H; Qing G
Clin Cancer Res; 2017 Jul; 23(14):3834-3846. PubMed ID: 28143869
[No Abstract] [Full Text] [Related]
33. Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias.
Rakowski LA; Garagiola DD; Li CM; Decker M; Caruso S; Jones M; Kuick R; Cierpicki T; Maillard I; Chiang MY
Cancer Res; 2013 Jan; 73(2):930-41. PubMed ID: 23161489
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.
Paganin M; Ferrando A
Blood Rev; 2011 Mar; 25(2):83-90. PubMed ID: 20965628
[TBL] [Abstract][Full Text] [Related]
35. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.
Franciosa G; Smits JGA; Minuzzo S; Martinez-Val A; Indraccolo S; Olsen JV
Nat Commun; 2021 May; 12(1):2507. PubMed ID: 33947863
[TBL] [Abstract][Full Text] [Related]
36. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition.
Habets RA; de Bock CE; Serneels L; Lodewijckx I; Verbeke D; Nittner D; Narlawar R; Demeyer S; Dooley J; Liston A; Taghon T; Cools J; de Strooper B
Sci Transl Med; 2019 May; 11(494):. PubMed ID: 31142678
[TBL] [Abstract][Full Text] [Related]
37. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.
Herranz D; Ambesi-Impiombato A; Sudderth J; Sánchez-Martín M; Belver L; Tosello V; Xu L; Wendorff AA; Castillo M; Haydu JE; Márquez J; Matés JM; Kung AL; Rayport S; Cordon-Cardo C; DeBerardinis RJ; Ferrando AA
Nat Med; 2015 Oct; 21(10):1182-9. PubMed ID: 26390244
[TBL] [Abstract][Full Text] [Related]
38. Direct inhibition of the NOTCH transcription factor complex.
Moellering RE; Cornejo M; Davis TN; Del Bianco C; Aster JC; Blacklow SC; Kung AL; Gilliland DG; Verdine GL; Bradner JE
Nature; 2009 Nov; 462(7270):182-8. PubMed ID: 19907488
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic mechanisms underlie resistance to NOTCH inhibition in T-ALL.
Cancer Discov; 2014 May; 4(5):OF11. PubMed ID: 24795015
[TBL] [Abstract][Full Text] [Related]
40. T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling.
Pear WS; Aster JC
Curr Opin Hematol; 2004 Nov; 11(6):426-33. PubMed ID: 15548998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
